Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
RETINOL PALMITATE ; ERGOCALCIFEROL ; CHOLINE CHLORIDE ; CYANOCOBALAMIN
Essential Pharmaceuticals Limited
A11BA
RETINOL PALMITATE ; ERGOCALCIFEROL ; CHOLINE CHLORIDE ; CYANOCOBALAMIN
0 %v/v
Infus/Pdr/Oral Soln
Product not subject to medical prescription
Multivitamins, plain
Marketed
1987-11-10
EP00104 EP00104 F1167 Important information about some of the ingredients of Ketovite Liquid This medicine contains methyl parahydroxybenzoate (E218), which may cause allergic reactions (possibly delayed). 3. HOW TO TAKE KETOVITE LIQUID Dosage Always take Ketovite Liquid exactly as your doctor has told you to. You should check with your doctor or pharmacist if you are not sure. The usual dose is 5 ml daily. If you take more Ketovite Liquid than you should Do not take more than you have been prescribed or than is recommended, as this may lead to too high a dose level, particularly of Vitamin A and Vitamin D. If you forget to take Ketovite Liquid You may take the dose later on during the same day. Do not take a double dose to make up for a forgotten dose. If you have any further questions on the use of this product, ask your doctor or pharmacist. 4. POSSIBLE SIDE EFFECTS There are usually no undesirable effects after taking Ketovite Liquid. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine. United Kingdom Yellow Card Scheme www.mhra.gov.uk/yellowcard Ireland HPRA Pharmacovigilance Earlsfort Terrace IRL - Dublin 2 Tel: +353 1 6764971 Fax: +353 1 6762517 www.hpra.ie email: medsafety@hpra.ie 5. HOW TO STORE KETOVITE LIQUID Keep out of the reach and sight of children. Do not use Ketovite Liquid after the expiry date which is stated on the bottle after Exp. Date. The expiry date refers to the last day of that month. Store in a refrigerator (2°C - 8°C). Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment. 6. FURTHER INFORMATION What Ketovite Liquid contains The active ingredients are vitamin A (as palmitate) 2500 I Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Ketovite Liquid 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5 ml contains: Excipients: also includes methyl parahydroxybenzoate (E218) 7.5mg/5ml For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Oral solution (oral liquid) Pale pinkish clear to opalescent liquid. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS As a sugar-free therapeutic supplement for the prevention of vitamin deficiency in conditions such as galactosaemia, disaccharide intolerance, phenylketonuria and other disorders of carbohydrate or amino acid metabolism, as well as in patients who are on restricted, specialised or synthetic diets. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For adults, children and the elderly: 5 ml daily, by oral administration. 4.3 CONTRAINDICATIONS Hypersensitivity to the product. Hypercalcaemia. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE The recommended dose should not be exceeded without medical advice. No other vitamin supplement containing Vitamins A and D should be taken with Ketovite Liquid except under medical supervision. The methyl parahydroxybenzoate (E218) in Ketovite Liquid may cause allergic reactions which can be delayed. Prolonged excessive ingestion of Vitamin A and Vitamin D can lead to hypervitaminosis states which may occur if foods high in this vitamin, (for example liver), are ingested in association with the recommended doses of this product. Vitamin A (as palmitate) 2500 IU Ergocalciferol (Vitamin D 2 ) 400 IU Cyanocobalamin 12.5 micrograms Choline chloride 150.0 mg H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ __ Read the complete document